Time–Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients

被引:0
作者
Hana Rac
Kayla R. Stover
Jamie L. Wagner
S. Travis King
Henderson D. Warnock
Katie E. Barber
机构
[1] University of Mississippi Medical Center,
[2] University of Mississippi School of Pharmacy,undefined
来源
Infectious Diseases and Therapy | 2017年 / 6卷
关键词
Ceftolozane/tazobactam; Cystic fibrosis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:507 / 513
页数:6
相关论文
共 58 条
[11]  
Gerard CJ(2014)Observation of “seesaw effect” with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains Infect Dis Ther 3 35-43
[12]  
Zurakowski D(1992)Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects Antimicrob Agents Chemother 36 552-557
[13]  
Nichols DP(1990)Pharmacokinetics of cefepime in subjects with renal insufficiency Clin Pharmacol Ther 48 268-276
[14]  
Pier GB(2005)Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the topic study: a randomised controlled trial Lancet 365 573-578
[15]  
Llanes C(2008)Pharmacokinetics of intravenous polymyxin B in critically ill patients Clin Infect Dis 47 1298-1304
[16]  
Pourcel C(2014)Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpreession and structural modification of AmpC Antimicrob Agents Chemother 58 3091-3099
[17]  
Richardot C(undefined)undefined undefined undefined undefined-undefined
[18]  
Riera E(undefined)undefined undefined undefined undefined-undefined
[19]  
Macia MD(undefined)undefined undefined undefined undefined-undefined
[20]  
Mena A(undefined)undefined undefined undefined undefined-undefined